Second-line treatment of recurrent HNSCC: tumor debulking in combination with high-dose-rate brachytherapy and a simultaneous cetuximab-paclitaxel protocol

BACKGROUND AND PURPOSE: After the failure of first-line treatment, the clinical prognosis in head and neck cancer (HNSCC) deteriorates. Effective therapeutic strategies are limited due to the toxicity of previous treatments and the diminished tolerance of surrounding normal tissue. This study demons...

Descripción completa

Detalles Bibliográficos
Autores principales: Ritter, M., Teudt, I. U., Meyer, J. E., Schröder, U., Kovács, G., Wollenberg, B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4719334/
https://www.ncbi.nlm.nih.gov/pubmed/26792072
http://dx.doi.org/10.1186/s13014-016-0583-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4719334/
https://www.ncbi.nlm.nih.gov/pubmed/26792072
http://dx.doi.org/10.1186/s13014-016-0583-0

Ejemplares similares